--- title: "CED, Coverage with Evidence Development | MedTech Terms" description: "Medicare paradigm conditioning coverage on participation in approved clinical studies or registries. Plain-English Reimbursement definition for MedTech teams, w" lang: en json-ld: | { "@context": "https://schema.org", "@graph": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/ced#term", "name": "Coverage with Evidence Development", "alternateName": "CED", "description": "Under CED, CMS provides coverage for promising items or services on the condition that beneficiaries are enrolled in an approved study or data collection effort that addresses outstanding questions.", "url": "https://medtechterms.com/terms/ced", "termCode": "ced", "inDefinedTermSet": { "@type": "DefinedTermSet", "name": "MedTech Terms", "url": "https://medtechterms.com/terms" } }, { "@type": "Article", "@id": "https://medtechterms.com/terms/ced#article", "headline": "CED, Coverage with Evidence Development", "description": "Medicare paradigm conditioning coverage on participation in approved clinical studies or registries.", "url": "https://medtechterms.com/terms/ced", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://medtechterms.com/terms/ced" }, "about": { "@id": "https://medtechterms.com/terms/ced#term" }, "articleSection": "Reimbursement", "inLanguage": "en", "keywords": "Coverage with Evidence Development, CED, Reimbursement, medical device, MedTech", "author": { "@type": "Person", "name": "Christian Espinosa", "jobTitle": "Founder, Blue Goat Cyber", "url": "https://bluegoatcyber.com" }, "publisher": { "@type": "Organization", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "isPartOf": { "@type": "WebSite", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "datePublished": "2026-05-05", "dateModified": "2026-05-05", "citation": [ { "@type": "CreativeWork", "name": "CMS CED", "url": "https://www.cms.gov/medicare/coverage/evidence", "publisher": { "@type": "Organization", "name": "CMS" } }, { "@type": "CreativeWork", "name": "AMA CPT Resources", "url": "https://www.ama-assn.org/practice-management/cpt", "publisher": { "@type": "Organization", "name": "AMA" } }, { "@type": "CreativeWork", "name": "AdvaMed - Payment & Coverage", "url": "https://www.advamed.org/our-work/", "publisher": { "@type": "Organization", "name": "AdvaMed" } } ], "mentions": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/ncd-lcd#term", "name": "National and Local Coverage Determinations", "alternateName": "NCD / LCD", "url": "https://medtechterms.com/terms/ncd-lcd" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/tcet#term", "name": "Transitional Coverage for Emerging Technologies", "alternateName": "TCET", "url": "https://medtechterms.com/terms/tcet" } ] }, { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://medtechterms.com/" }, { "@type": "ListItem", "position": 2, "name": "Terms", "item": "https://medtechterms.com/terms" }, { "@type": "ListItem", "position": 3, "name": "Reimbursement", "item": "https://medtechterms.com/terms?cat=Reimbursement" }, { "@type": "ListItem", "position": 4, "name": "Coverage with Evidence Development", "item": "https://medtechterms.com/terms/ced" } ] }, { "@type": "FAQPage", "@id": "https://medtechterms.com/terms/ced#faq", "mainEntity": [ { "@type": "Question", "name": "What is the primary goal of Coverage with Evidence Development (CED)?", "acceptedAnswer": { "@type": "Answer", "text": "The primary goal of CED is to facilitate patient access to promising new medical technologies while simultaneously gathering additional clinical evidence to determine their long-term effectiveness and appropriateness for coverage." } }, { "@type": "Question", "name": "Which regulatory body most commonly implements CED?", "acceptedAnswer": { "@type": "Answer", "text": "The Centers for Medicare & Medicaid Services (CMS) in the United States is the primary body that implements Coverage with Evidence Development (CED) for novel medical devices and services." } }, { "@type": "Question", "name": "How does CED impact manufacturer strategy?", "acceptedAnswer": { "@type": "Answer", "text": "CED significantly impacts manufacturer strategy by requiring them to plan for post-market evidence generation, including study design, data collection, and patient enrollment, in conjunction with their regulatory approval processes." } } ] } ] } --- [ MedTech Terms The authoritative reference ](/) Browse Learn [Latest](/latest) About 1. [Home](/) 2. / 3. [Terms](/terms) 4. / 5. [Reimbursement](/terms?cat=Reimbursement) 6. / 7. Coverage with Evidence Development [All terms](/terms) Reimbursement [Clinical Evidence](/ecosystems/clinical-evidence)[Hospital Buyer & Reimbursement](/ecosystems/hospital-buyer)CED # Coverage with Evidence Development Medicare paradigm conditioning coverage on participation in approved clinical studies or registries. Reviewed by [Christian Espinosa, Founder, Blue Goat Cyber](/authors/christian-espinosa) Last reviewed May 5, 2026 ## Definition Under CED, CMS provides coverage for promising items or services on the condition that beneficiaries are enrolled in an approved study or data collection effort that addresses outstanding questions. What the regulation says Coverage with Evidence Development (CED) is a mechanism primarily used by the Centers for Medicare & Medicaid Services (CMS) in the United States to provide conditional coverage for medical technologies. This approach enables beneficiaries to access innovative items and services while systematically collecting additional evidence to assess their impact on health outcomes. The conditions for coverage often involve participation in studies or registries, as outlined by CMS policies. ## What this means in practice CED is common for novel devices with developing evidence (e.g., TAVR, leadless pacemakers historically). Registry participation requirements influence hospital adoption and total cost of evidence generation. ## Examples - A novel cardiac implant receives CED from CMS, requiring all patients receiving the device to be enrolled in a specific post-market registry to collect long-term outcome data. - A new diagnostic test is covered under CED, mandating that healthcare providers submit data on patient demographics and test results to a designated database to assess its clinical utility. - CMS grants CED for a new cancer therapy, contingent on patients participating in an approved clinical trial that aims to further evaluate its efficacy in a broader patient population. Common pitfalls - • Manufacturers might underestimate the resources required for data collection and study participation under CED. - • Failing to design studies that adequately address the evidence gaps identified by CMS can lead to delays or non-coverage. - • Misinterpreting CMS requirements for data submission and study protocols can result in compliance issues. - • Assuming that CED implies permanent coverage without the need for submitting conclusive evidence is a common misconception. - • Ignoring the impact of CED on market access strategies and product launch timelines can lead to commercial challenges. ## Frequently asked questions What is the primary goal of Coverage with Evidence Development (CED)? The primary goal of CED is to facilitate patient access to promising new medical technologies while simultaneously gathering additional clinical evidence to determine their long-term effectiveness and appropriateness for coverage. Which regulatory body most commonly implements CED? How does CED impact manufacturer strategy? ## Cross-references ### Used by Things that build on this term. - [ National and Local Coverage Determinations(NCD / LCD) ](/terms/ncd-lcd) ## Related terms Grouped by theme ### Editor's picks · Hand-selected related concepts [ Reimbursement National and Local Coverage Determinations(NCD / LCD) Medicare coverage policies issued nationally (NCD) or by individual MAC contractors (LCD). ](/terms/ncd-lcd)[ Reimbursement Transitional Coverage for Emerging Technologies(TCET) CMS pathway providing time-limited Medicare coverage for FDA-designated Breakthrough Devices. ](/terms/tcet) ### More in Reimbursement · Same category [ Reimbursement 340B Drug Pricing Program(340B) Federal program providing discounted drugs to safety-net providers. ](/terms/340b)[ Reimbursement Ambulatory Payment Classification(APC) The Medicare grouping system that determines hospital outpatient payment amounts under OPPS, analogous to MS-DRGs for inpatient. ](/terms/apc)[ Reimbursement ASC Site-of-Service Shift Migration of procedures from hospitals to ambulatory surgery centers. ](/terms/asc-shift)[ Reimbursement Budget Impact Model(BIM) Financial model that estimates the total cost consequences of adopting a new technology to a payer's budget over a defined horizon. ](/terms/budget-impact-model) Cited by Where this term appears across MedTech Terms. Ecosystems (2) - [Clinical Evidence](/ecosystems/clinical-evidence) - [Hospital Buyer & Reimbursement](/ecosystems/hospital-buyer) ## Primary references 3 sources Link health: 3 verified · last checked 2026-06-20 CMS· 1 AMA· 1 AdvaMed· 1 1. [1 CMS CED Verified CMS · cms.gov ](https://www.cms.gov/medicare/coverage/evidence) 2. [2 AMA CPT Resources Verified AMA · ama-assn.org ](https://www.ama-assn.org/practice-management/cpt) 3. [3 AdvaMed - Payment & Coverage Verified AdvaMed · advamed.org ](https://www.advamed.org/our-work/) Inline markers like \[1\] jump to the matching reference above. Sponsor note ### Need cybersecurity expertise on a connected-device launch? Blue Goat Cyber helps MedTech teams ship connected products that hospital security teams will actually procure. [Book a 30-minute discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) - No obligation - Expert-led from minute one - NDA available on request MedTech Terms is a community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com). Definitions are independent of any vendor. On this term Category Reimbursement Acronym CED Sources 3 Updated 5/5/2026 [Compare with another term](/compare?a=ced) Learn in 60 seconds Card Lesson Quiz Medicare paradigm conditioning coverage on participation in approved clinical studies or registries. - · CED is common for novel devices with developing evidence (e.g., TAVR, leadless pacemakers historically). - · Registry participation requirements influence hospital adoption and total cost of evidence generation. Remember this Watch out: Manufacturers might underestimate the resources required for data collection and study participation under CED. Related terms - [National and Local Coverage Determinations(NCD / LCD) ](/terms/ncd-lcd) - [Transitional Coverage for Emerging Technologies(TCET) ](/terms/tcet) You may also need Auto-suggested from Reimbursement and shared keywords. - [CMS IDE Coverage (Category A & B) ](/terms/ide-coverage) - [Post-Market Clinical Follow-up(PMCF) ](/terms/pmcf) - [Durable Medical Equipment, Prosthetics, Orthotics, and Supplies(DMEPOS) ](/terms/dmepos) - [RWE for Reimbursement ](/terms/real-world-evidence-reimbursement) - [Contract Research Organization(CRO) ](/terms/cro) - [First-in-Human Study(FIH) ](/terms/fih) [All Reimbursement terms](/terms?cat=Reimbursement) MedTech Terms An authoritative, plain-language reference for the regulatory, quality, cybersecurity, and software terms that shape modern medical devices. Browse - [All terms](/terms) - [A–Z index](/a-z) - [Categories](/categories) - [Ecosystems](/ecosystems) - [Learning paths](/paths) - [Compare terms](/compare) - [Quiz](/quiz) Resources - [FDA Medical Devices](https://www.fda.gov/medical-devices) - [EU MDR](https://eur-lex.europa.eu/eli/reg/2017/745/oj) - [IMDRF](https://www.imdrf.org/) - [Methodology](/methodology) - [Changelog](/changelog) - [Editor: Christian Espinosa](/authors/christian-espinosa) - [About this site](/about) © 2026 MedTech Terms. Reference content for educational purposes - not regulatory advice. A community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com)